Copenhagen, Denmark

Anne Finne Pihl

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Hvidovre Hospital. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anne Finne Pihl. Retrieved from https://idiyas.com/inventor/anne-finne-pihl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Anne Finne Pihl: Innovator in Virus Purification

Introduction

Anne Finne Pihl is an accomplished inventor based in København Ø, Denmark. She has made significant contributions to the field of virus purification, particularly in the context of Hepatitis C virus (HCV) particles. Although she currently holds no granted patents, her innovative work is noteworthy.

Latest Patent Applications

Anne Finne Pihl's latest patent application is titled "Method of Purifying Whole Virus Particles." This invention relates to a method for purifying whole HCV particles, which includes several steps: providing a cell culture supernatant containing virus particles, purifying and concentrating the supernatant, and further purifying the product using steric exclusion chromatography at alkaline pH. The method also involves using sulphated cellulose membrane absorbers to obtain purified whole virus particles.

Conclusion

Anne Finne Pihl's work in the field of virus purification showcases her dedication to advancing medical science. Her innovative methods have the potential to impact the treatment of viral infections significantly.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…